About
Dr. Lars Hedbys is a member of the Ventac Partners team since 2006. He has over 30 years of life science industry and science experience including over 20 years in senior and executive management positions. Dr. Hedbys is co-founder and CEO of Idogen AB, a publicly traded company listed on AktieTorget in Stockholm. Idogen is an innovative company with the aim of introducing the first tolerogenic vaccine. Lars Hedbys is also serving as Chairman of the Board of Lund Life Science Incubator. This is a not for profit company dedicated to providing business development support and state of the art laboratory facilities to life science start-up companies. Dr. Hedbys is also co-founder of Regenesance BV (The Netherlands) and Casigen Pharma Ltd (Hong Kong). Lars Hedbys contributes with an extensive experience in drug development, product strategy development and business development. He has a track record of leading large operational organizations, organizations in change as well as building a
Position in the VCSift Database
- • 14 investors at Ventac Partners are tracked.
- • 2,531 investors hold the Partner role in VCSift. Lars Hedbys is one of them.
- • 92 investors are based in Sweden.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Sweden
Contact Information
Find more investors like Lars
Search Investors